CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.

doi:10.1002/path.5584

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.

The Journal of pathology - 1 Feb 2021

Viotto Davide, Russo Francesca, Anania Ilaria, Segatto Ilenia, Rampioni Vinciguerra Gian Luca, Dall'Acqua Alessandra, Bomben Riccardo, Perin Tiziana, Cusan Martina, Schiappacassi Monica, Gerratana Lorenzo, D'Andrea Sara, Citron Francesca, Vit Filippo, Musco Lorena, Mattevi Maria Chiara, Mungo Giorgia, Nicoloso Milena S, Sonego Maura, Massarut Samuele, Sorio Roberto, Barzan Luigi, Franchin Giovanni, Giorda Giorgio, Lucia Emilio, Sulfaro Sandro, Giacomarra Vittorio, Polesel Jerry, Toffolutti Federica, Canzonieri Vincenzo, Puglisi Fabio, Gattei Valter, Vecchione Andrea, Belletti Barbara, Baldassarre Gustavo

Abstract excerpt

The CDKN1B gene, encoding for the CDK inhibitor p27kip1 , is mutated in defined human cancer subtypes, including breast, prostate carcinomas and small intestine neuroendocrine tumors. Lessons learned from small intestine neuroendocrine tumors suggest that CDKN1B mutations could be subclonal, raising the question of whether a deeper sequencing approach could lead to the identification of higher numbers of patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p27

Share to DNA Copy Number Variations

Share to Intestinal Neoplasms

Share to MCF-7 Cells

Share to Mutation

Share to Neuroendocrine Tumors

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33140857
DOI: 10.1002/path.5584
PMCID: PMC7839435

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.PMID 33140857Read ↗

Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human TumorsSemantic proximity Read ↗

Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors.Semantic proximity Read ↗

Somatic mutation of CDKN1B in small intestine neuroendocrine tumors.Semantic proximity Read ↗

Luminal breast epithelial cells of BRCA1 or BRCA2 mutation carriers and noncarriers harbor common breast cancer copy number alterations.Semantic proximity Read ↗

Luminal breast epithelial cells from wildtype and <i>BRCA</i> mutation carriers harbor copy number alterations commonly associated with breast cancerSemantic proximity Read ↗

Genome-wide analysis of copy number alterations led to the characterisation of PDCD10 as oncogene in ovarian cancerSemantic proximity Read ↗

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.Semantic proximity Read ↗

The unpredictable consequences of CDKN1B/p27Kip1 mutations in cancer.Semantic proximity Read ↗

p27Kip1 and Tumors: Characterization of CDKN1B Variants Identified in MEN4 and Breast CancerSemantic proximity Read ↗

CDKN1C/p57kip2is a candidate tumor suppressor gene in human breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.